NFE2L2 and cancer: In addition, the inhibition of flavonoids such as hesperidin, naringin, quercetin, luteolin, and apigenin on NF-κB, ERK1/2, AP1, TNF-α, PKC, and Nrf2 pathways has been proved to have significant pharmacological activities on a variety of cancers, including hepatocellular carcinoma, colon cancer, breast cancer, lung cancer, cervical cancer, and bladder cancer.